Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Brenzys | Etanercept | Rheumatoid arthritis, Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bijuva | estradiol and progesterone | Vasomotor symptoms associated with menopause | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Aptiom | Eslicarbazepine acetate | Epilepsy, partial-onset seizures | List with criteria/condition | Complete | ||
| Spravato | esketamine hydrochloride | Major depressive disorder (MDD), adults | Do not reimburse | Complete | ||
| Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Withdrawn | |||
| Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Do not list | Complete | ||
| Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Tarceva | Erlotinib | Cancer, Lung , non-small cell | List with clinical criteria and/or conditions | Complete |
Last Updated : May 16, 2024